Several other research analysts have also weighed in on KIN. HC Wainwright reissued a buy rating and set a $16.00 price target (down from $17.50) on shares of Kindred Biosciences in a research report on Wednesday, November 13th. Zacks Investment Research raised Kindred Biosciences from a sell rating to a hold rating in a research report on Saturday, November 16th. Finally, ValuEngine lowered Kindred Biosciences from a strong-buy rating to a buy rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $13.94.
Shares of Kindred Biosciences stock traded up $0.06 on Tuesday, reaching $7.49. 5,035 shares of the company were exchanged, compared to its average volume of 89,818. The stock has a fifty day moving average price of $7.69 and a 200-day moving average price of $7.74. The firm has a market capitalization of $292.80 million, a price-to-earnings ratio of -4.68 and a beta of 0.45. The company has a current ratio of 9.30, a quick ratio of 8.88 and a debt-to-equity ratio of 0.21. Kindred Biosciences has a fifty-two week low of $5.96 and a fifty-two week high of $13.96.
Hedge funds have recently modified their holdings of the business. PARK CIRCLE Co acquired a new position in Kindred Biosciences in the 2nd quarter worth about $27,000. Bank of Montreal Can increased its position in Kindred Biosciences by 2,368.3% in the 2nd quarter. Bank of Montreal Can now owns 3,505 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 3,363 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in Kindred Biosciences in the 3rd quarter worth about $46,000. Marshall Wace LLP acquired a new position in Kindred Biosciences in the 1st quarter worth about $53,000. Finally, Gabelli Funds LLC acquired a new position in Kindred Biosciences in the 2nd quarter worth about $108,000. 68.63% of the stock is currently owned by institutional investors.
About Kindred Biosciences
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Recommended Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.